Molecular Markers in Occupational Chronic Obstructive Pulmonary Disease Comorbid with Heart Failure

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Background. Comorbid heart failure (HF) is common in chronic obstructive pulmonary disease (COPD). Comorbid condition features are studied well in COPD due to tobacco smoke. There is a lack of data about mechanisms, clinical and functional specificity of occupational COPD and HF comorbidity. As occupational COPD and HF share common symptoms and sometimes lung function disorders, there is an unmet need in new markers of HF in occupational COPD. Aims — to establish molecular markers associated with occupational COPD with HF comorbidity. Methods. Subjects with occupational COPD were enrolled in a single-center prospective cohort observational study. Comparison group — COPD due to tobacco smoke. Then groups were stratified according to HF so the following subgroups were compared: occupational COPD with HF (n = 63), occupational COPD without HF (n = 52), COPD due to tobacco smoke with HF (n = 41), COPD due to tobacco smoke without HF (n = 74). Control group — healthy people (n = 115). Groups were matched by demographics, duration of COPD and HF. CODP was diagnosed according to GOLD 2011–2020 criteria, HF — according to Russian Federal clinical guidelines. Occupational etiological factors were silica dust, organic solvents, metal fumes. Clinical and functional characteristics of CODP and HF were obtained. Serum levels of pulmonary and activation-regulated chemokine (PARC/CCL-18), protein S100β, troponin, N terminal pro brain natriuretic peptide (NT-pro-BNP), von Willebrand factor, C-reactive protein were measured by enzyme linked immunosorbent assay, fibrinogen were measured by Clauss method, lactate dehydrogenase, creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase were measured by standard biochemical method. Data are presented as median and interquartile range. Linear regression were used to explore relationships. Results. The molecular specificity of occupational COPD comorbid with HF were the largest increase in serum concentration of PARC-CCL18, NT-pro-BNP, protein S100β, troponin, von Willebrand factor and fibrinogen. This factors were associated with length of service. For PARC-CCL18 В = 1.1; for NT-pro-BNP В = 0.9; for protein S100β В = 1.3; for troponin В = 0.8, for von Willebrand factor В = 1.5 and for fibrinogen В = 1.1. Molecular factors also were related to phenotype characteristics of COPD and HF. In multiply regression model the best predictors of comorbidity of CODP and HF were PARC-CCL18 (В = 1.1; р = 0.002), NT-pro-BNP (В = 1.5; р = 0.001), protein S100β (В = 1.2; р = 0.002), troponin (В = 0.9; р = 0.003). The model was adjusted for gender, age, duration of CODP and HF, FEV1. Conclusions. Occupational CODP comorbid with heart failure is the distinct phenotype. The perspective molecular markers of this phenotype are serum levels of PARC-CCL18, NT-pro-BNP, protein S100β, troponin.


Full Text

Restricted Access

About the authors

Lyubov A. Shpagina

Novosibirsk State Medical University

Email: lashpagina@gmail.com
ORCID iD: 0000-0003-0871-7551
SPIN-code: 5773-6649

Russian Federation, Novosibirsk

MD, PhD, Professor

Natal’ya V. Kamneva

Novosibirsk State Medical University

Email: mkb-2@yandex.ru
ORCID iD: 0000-0003-3251-0315
SPIN-code: 8868-3043

Russian Federation, Novosibirsk

PhD Student

Ilya Semenovich Shpagin

Novosibirsk State Medical University

Email: mkb-2@yandex.ru
ORCID iD: 0000-0002-3109-9811
SPIN-code: 2892-6184

Russian Federation, Novosibirsk

MD, PhD, Assistant Professor

Olga S. Kotova

Novosibirsk State Medical University

Author for correspondence.
Email: ok526@yandex.ru
ORCID iD: 0000-0003-0724-1539
SPIN-code: 2488-0659

Russian Federation, Novosibirsk

MD, PhD, Assistant Professor

Ekaterina V. Anikina

Novosibirsk State Medical University

Email: mkb-2@yandex.ru
ORCID iD: 0000-0002-6047-1707
SPIN-code: 3847-0025

Russian Federation, Novosibirsk

PhD Student

Dmitrij A. Gerasimenko

Novosibirsk State Medical University

Email: mkb-2@yandex.ru
ORCID iD: 0000-0001-5694-2206

Russian Federation, Novosibirsk

PhD Student

References

  1. Карамнова Н.С., Шальнова С.А., Деев А.Д., и др. Статус курения и характер питания взрослой популяции: отличия рационов. Результаты эпидемиологического исследования ЭССЕ-РФ // Российский кардиологический журнал. — 2018. — № 6. — С. 131–140. [Karamnova NS, Shalnova SA, Deev AD, et al. Smoking status and nutrition type of alult population: variety of meals. Results from the ESSE-RF study. Russ J Cardiol. 2018;23(6):131–140. (In Russ.)]. doi: https://doi.org/10.15829/1560-4071-2018-6-131-140
  2. Institute for Health Metrics and Evaluation. GBD Compare. Viz Hub. Available from: https://vizhub.healthdata.org/gbd-compare/ (accessed: 21.06.2020).
  3. GBD 2016 occupational chronic respiratory risk factors collaborators. Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. Occup Environ Med. 2020;77(3):142–150. doi: https://doi.org/10.1136/oemed-2019-106013
  4. Paulin LM, Diette GB, Blanc PD, et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(5):557–565. doi: https://doi.org/10.1164/rccm.201408-1407OC
  5. Шпагина Л.А., Котова О.С., Шпагин И.С., Герасименко О.Н. Профессиональная хроническая обструктивная болезнь легких: фенотипические характеристики // Медицина труда и промышленная экология. — 2017. — № 3. — С. 47–53. [Shpagina LA, Kotova OS, Shpagin IS, Gerasimenko ON. Occupational chronic obstructive lung disease: phenotypic characteristics. Med Tr Prom Ekol. 2017;3:47–53. (In Russ.)]
  6. Carter P, Lagan J, Fortune C, et al. Association of Cardiovascular Disease with Respiratory Disease. J Am Coll Cardiol. 2019;73(17):2166–2177. doi: https://doi.org/10.1016/j.jacc.2018.11.063
  7. Ellingsen J, Johansson G, Larsson K, et al. Impact of Comorbidities and Commonly Used Drugs on Mortality in COPD — Real-World Data from a Primary Care Setting. Int J Chron Obstruct Pulmon Dis. 2020;15:235–245. doi: https://doi.org/10.2147/COPD.S231296
  8. Santibáñez M, Garrastazu R, Ruiz-Nuñez M, et al. Predictors of Hospitalized Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease. PLoS One. 2016; 11(6):e0158727. doi: https://doi.org/10.1371/journal.pone.0158727
  9. Lawson CA, Mamas MA, Jones PW, et al. Association of Medication Intensity and Stages of Airflow Limitation with the Risk of Hospitalization or Death in Patients with Heart Failure and Chronic Obstructive Pulmonary Disease. JAMA Netw Open. 2018;1(8):e185489. doi: https://doi.org/10.1001/jamanetworkopen.2018.5489
  10. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185. doi: https://doi.org/10.1183/09031936.00128008
  11. Fisk M, McEniery CM, Gale N, et al. Surrogate Markers of Cardiovascular Risk and Chronic Obstructive Pulmonary Disease: a Large Case-Controlled Study. Hypertension. 2018;71(3):499–506. doi: https://doi.org/10.1161/HYPERTENSIONAHA.117.10151
  12. Hilde JM, Skjørten I, Grøtta OJ, et al. Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. J Am Coll Cardiol. 2013;62(12):1103–1111. doi: https://doi.org/10.1016/j.jacc.2013.04.091
  13. Zhyvotovska A, Yusupov D, Kamran H, et al. Diastolic Dysfunction in Patients with Chronic Obstructive Pulmonary Disease: a Meta-Analysis of Case Controlled Studies. Int J Clin Res Trials. 2019;4(2):137. doi: https://doi.org/10.15344/2456-8007/2019/137
  14. Третьяков С.В., Шпагина Л.А. Спировелоэргометрия в оценке физической работоспособности лиц, подвергающихся воздействию органических растворителей // Медицина труда и промышленная экология. — 2015. — № 6. — С. 27–31. [Tretiakov SV, Shpagina LA. Spirometry and veloergometry in evaluating physical performance of individuals exposed to organic solvents. Med Tr Prom Ekol. 2015;(6):27–31. (In Russ.)]
  15. Brenner S, Güder G, Berliner D, et al. Airway obstruction in systolic heart failure-COPD or congestion? Int J Cardiol. 2013;168(3):1910–1916. doi: https://doi.org/10.1016/j.ijcard.2012.12.083
  16. Авдеев С.Н., Гайнитдинова В.В., Царева Н.А., Мержоева З.М. Натрийуретические пептиды как маркеры развития и прогноза тяжести легочной гипертензии у больных хронической обструктивной болезнью легких // Клиническая лабораторная диагностика. — 2018. — Т. 63. — № 6. — С. 333–337. [Avdeev SN, Gaynitdinova VV, Tsareva NA, Merzhoeva ZM. Natriuretic peptides as markers of development and prognosis of the severity of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Klinicheskaya Laboratornaya Diagnostika. 2018;63(6):333–337. (In Russ.)] doi: https://doi.org/10.18821/0869-2084-2018-63-6-333-337
  17. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 reprot). Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed: 21.06.2020).
  18. Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Клинические рекомендации ОССН–РКО–РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение // Кардио-логия. — 2018. — Т. 58. – № S6. — С. 1–164. [Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (AHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(S6):1–164. (In Russ.)]. doi: https://doi.org/10.18087/cardio.2475
  19. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi: https://doi.org/10.1183/09031936.00102509
  20. Pierobon A, Ranzini L, Torlaschi V, et al. Screening for neuropsychological impairment in COPD patients undergoing rehabilitation. PLoS One. 2018;13(8):e0199736. doi: https://doi.org/10.1371/journal.pone.0199736
  21. Lock-Johansson S, Vestbo J, Sorensen GL. Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. Respir Res. 2014;15:147. doi: https://doi.org/10.1186/s12931-014-0147-5
  22. Muñoz-Esquerre M, Aliagas E, López-Sánchez M, et al. Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine). PLoS One. 2017;12(5):e0177218. doi: https://doi.org/10.1371/journal.pone.0177218
  23. Khanam SS, Choi E, Son JW, et al. Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure. PLoS One. 2018;13(11):e0206380. doi: https://doi.org/10.1371/journal.pone.0206380
  24. Pavasini R, Tavazzi G, Biscaglia S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117–126. doi: https://doi.org/10.1177/1479972316674393
  25. Donato R, Cannon BR, Sorci G, et al. Functions of S100 proteins. Curr Mol Med. 2013;13(1):24–57.
  26. Alexandre F, Heraud N, Sanchez AM, et al. Brain Damage and Motor Cortex Impairment in Chronic Obstructive Pulmonary Disease: Implication of Nonrapid Eye Movement Sleep Desaturation. Sleep. 2016;39(2):327–335. doi: https://doi.org/10.5665/sleep.5438
  27. Li J, Fei GH. The unique alterations of hippocampus and cognitive impairment in chronic obstructive pulmonary disease. Respir Res. 2013;14(1):140. doi: https://doi.org/10.1186/1465-9921-14-140
  28. Neukamm A, Einvik G, Didrik Høiseth A, et al. The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients. BMC Pulm Med. 2016;16(1):164. doi: https://doi.org/10.1186/s12890-016-0319-9
  29. Hattori K, Ishii T, Motegi T, et al. Relationship between serum cardiac troponin T level and cardiopulmonary function in stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:309–320. doi: https://doi.org/10.2147/COPD.S76293
  30. Langholm LL, Rønnow SR, Sand JMB, et al. Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk. Int J Chron Obstruct Pulmon Dis. 2020;15:543–552. doi: https://doi.org/10.2147/COPD.S235673

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract - 40

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies